1. Generics Bulletin

Teva Stresses Stability In Settling Oklahoma Opioids Case

 
• By Aidan Fry

Teva says paying $85m to settle claims it contributed to opioid abuse in Oklahoma is important in maintaining the stability of the heavily indebted group.

Oklahoma_Pin
By settling opioid abuse litigation in Oklahoma, Teva may have earned itself some legal breathing space • Source: Shutterstock

Teva says its keeping “the long-term stability of the company at the forefront” by agreeing to pay $85m to settle claims brought by the US state of Oklahoma over the company’s alleged “role in fueling the state’s opioid epidemic” through its marketing practises for both generic analgesics and fentanyl brands such as Actiq and Fentora.

Stressing that the settlement did not establish any wrongdoing and that “Teva has not contributed to the abuse of opioids in Oklahoma in any way”, the Israeli group said it was “pleased to put the Oklahoma case behind it and remains prepared to vigorously defend claims against the company,

More from Business

More from Generics Bulletin

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Teva To Slash Thousands Of Jobs And Shut More Sites Under $700m Savings Plan

 
• By Dean Rudge

Teva’s plans to generate net savings of $700m by 2027 have been described by the firm as a journey and not a destination, with the suggestion that “this era of cost efficiency, harmonization, frugality will continue.”

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.